Summary
We conducted a phase I clinical study of aziridinylbenzoquinone (Diaziquone, AZQ) given as a 4 hour infusion weekly × 4. Forty-five children with recurrent acute leukemia and 33 children with various advanced solid tumors participated. Severe myelosuppression was the dose limiting toxic effect, occurring in all patients at the upper dose levels. Gastrointestinal and hepatic toxicities were infrequent and not severe. No allergic reactions occurred. Objective tumor regression was noted in 3 of 25 patients with a CNS tumor and in 6 of 45 patients with acute leukemia. For phase II trials the recommended dosage of Diaziquone given by this schedule is 18 mg/M2×4 for patients with a solid tumor, and is 30 mg/M2/week × 4 for children with acute leukemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bedikian AY, Bodey GP, Burgess MA, Freireich EJ: Phase I Study of Aziridinylbenzoquinone (NSC 182986). Cancer Clin Trais 4:459–463, 1981
Bjornsson TD, Schold SC, Friedman HS, Schneider D, Falletta JM: Pharmacokinetics of Diaziquone After Three Different Dosage Regimens. Cancer Treatment Reports 69:1383–1385, 1985
Vietti TJ: Evaluation of toxicity: Clinical Issues. Cancer Treat Rep 64:457–461, 1980
Egorin MG, Fox BM, Spiegel JF, Gutierrez PL, Friedman RD, Bachur NR: The Cellular Pharmacology of Aziridinyl- benzoquinone (AZQ) (NSC 18296) (Abstr). Proc Amer Assoc Can Res 23:177, 1982
Schold SC, Friedman HS, Bjornsson TD, Falletta JM: Treatment of Patients with Recurrent Primary Brain Tumors with Diaziquone. Neurology 34:615–619, 1984
Schold SC, Mahaley MS, Vick NA, Friedman HS, Burger PC, DeLong ER, Albright RE, Bullard DE, Khandekar JD, Cairncross JG, Macdonald DR, Falletta JM: Phase II Diaziquone-Based Chemotherapy Trials in Patients with Anaplastic Supratentorial Astrocytic Neoplasms. J Clin Onc 5:464–471, 1987
Lee EJ, Van Echo DA, Egorin MJ, Balchandran MS, Schulman P, Schiffer C: Diaziquone Given as a Continuous Infusion Is an Active Agent for Relapsed Adult Acute Nonlymphocytic Leukemia. Blood 5:464–471, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Falletta, J.M., Cushing, B., Lauer, S. et al. Phase I evaluation of diaziquone in childhood cancer. Invest New Drugs 8, 167–170 (1990). https://doi.org/10.1007/BF00177252
Issue Date:
DOI: https://doi.org/10.1007/BF00177252